Research programme: CT antigen antibodies - CT Atlantic
Latest Information Update: 28 Aug 2020
Price :
$50 *
At a glance
- Originator CT Atlantic AG
- Developer CT Atlantic AG; Ludwig Institute for Cancer Research; University of Zurich
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in Switzerland
- 05 Jul 2016 Early research in Cancer in Switzerland (unspecified route)